Savara Inc Share-based Payment Arrangement, Accelerated Cost
Savara Inc (SVRA) reported Share-based Payment Arrangement, Accelerated Cost of $100.00 thousand for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2017-08-09
- Savara Inc share-based payment arrangement, accelerated cost for fiscal 2014 was $300.00K.
| Period end | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|---|
| 2017-06-30 | $100.00K 10-Q · filed 2017-08-09 | |
| 2014-12-31 | $300.00K 10-K · filed 2015-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |